{
    "id": "9132607",
    "text": "Zanolimumab (expected trade name HuMax-CD4Genmab initiates Phase II Study with HuMax-CD4 ) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association. Development of the drug was ultimately discontinued with termination of all trials. == References == Category:Monoclonal antibodies ",
    "title": "Zanolimumab"
}